SCHEMBL7149185

SCHEMBL7149185

Nc1nc(OCc2ccccn2)c(I)c(-c2ccco2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 15/20 0.51
ADORA1 P30542 12/20 0.51
ADORA2B P29275 6/20 0.51
ADORA3 P0DMS8 6/20 0.51
MGMT P16455 1/20 0.46
GABRA1 P14867 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRA5 P31644 1/20 0.42
GABRA3 P34903 1/20 0.42
GABRA2 P47869 1/20 0.42
TLR7 Q9NYK1 2/20 0.39
TLR8 Q9NR97 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
THRB P10828 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7153412 0.87 ADORA2A (0.52) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL5046435 0.86 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL7149495 0.86 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL7149520 0.86 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL7147379 0.84 ADORA2A (0.49) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL5041663 0.83 ADORA2A (0.56) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL7142558 0.80 ADORA2A (0.46) ADORA2AADORA1ADORA2BKDM4EMEN1
SCHEMBL7171290 0.78 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3
SCHEMBL7147897 0.77 ADORA2A (0.43) ADORA2AADORA1ADORA2BADORA3
SCHEMBL5046603 0.77 ADORA2A (0.53) ADORA2AADORA1ADORA2BADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.